La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.

Company profile
Ticker
LJPC
Exchange
Website
CEO
Larry Edwards
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
SEC CIK
Corporate docs
Subsidiaries
La Jolla Pharma, LLC • Tetraphase Pharmaceuticals, Inc. • La Jolla Pharmaceutical Holdings, LLC • Tetraphase Pharma Securities, Inc. • La Jolla Pharmaceutical Australia Pty Ltd • La Jolla Pharmaceutical I B.V. • La Jolla Pharmaceutical II B.V. • La Jolla Pharmaceutical III B.V. • Tetraphase Ireland Limited ...
IRS number
330361285
LJPC stock data
News

Stocks That Hit 52-Week Lows On Wednesday
15 Jun 22
Stocks That Hit 52-Week Lows On Tuesday
14 Jun 22
Stocks That Hit 52-Week Lows On Monday
13 Jun 22
Recap: La Jolla Pharmaceutical Q1 Earnings
16 May 22
La Jolla Pharmaceutical Q1 EPS $0.00 Vs. $0.42 YoY, Sales $10.40M Down From $34.14M YoY
16 May 22
Investment data
Securities sold
Number of investors
Calendar
16 May 22
2 Jul 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 44.21M | 44.21M | 44.21M | 44.21M | 44.21M | 44.21M |
Cash burn (monthly) | 833K | (no burn) | 682K | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 2.55M | n/a | 2.09M | n/a | n/a | n/a |
Cash remaining | 41.66M | n/a | 42.12M | n/a | n/a | n/a |
Runway (months of cash) | 50.0 | n/a | 61.8 | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jun 22 | Michael S Hearne | Common Stock | Grant | Acquire A | No | No | 2.72 | 236 | 641.92 | 9,950 |
15 Jun 22 | Michael S Hearne | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.2 | 236 | 755.2 | 236 |
31 May 22 | Michael S Hearne | Common Stock | Grant | Acquire A | No | No | 3.4085 | 189 | 644.21 | 9,714 |
31 May 22 | Michael S Hearne | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.01 | 189 | 757.89 | 189 |
13 May 22 | Michael S Hearne | Common Stock | Grant | Acquire A | No | No | 3.4085 | 188 | 640.8 | 9,525 |
13 May 22 | Michael S Hearne | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.01 | 188 | 753.88 | 188 |
29 Apr 22 | Michael S Hearne | Common Stock | Grant | Acquire A | No | No | 3.468 | 185 | 641.58 | 9,337 |
29 Apr 22 | Michael S Hearne | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.08 | 185 | 754.8 | 185 |
14 Apr 22 | Michael S Hearne | Common Stock | Grant | Acquire A | No | No | 3.7145 | 173 | 642.61 | 9,152 |
14 Apr 22 | Michael S Hearne | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 173 | 756.01 | 173 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 45 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 6 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 104.93M |
Total shares | 26.1M |
Total puts | 0 |
Total calls | 22.6K |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tang Capital Partners | 9.61M | $34.49M |
Tang Capital Management | 9.61M | $41.03M |
RTW Investments | 2.33M | $9.94M |
Vanguard | 825.48K | $3.53M |
HealthInvest Partners AB | 707K | $3.02M |
D. E. Shaw & Co. | 600.07K | $2.56M |
Acadian Asset Management | 477.69K | $2.04M |
BLK Blackrock | 426.51K | $1.82M |
Tang Kevin C | 240K | $1.03M |
Geode Capital Management | 202.82K | $866K |
Financial report summary
?Competition
Pfizer • Eagle Pharmaceuticals • Biocryst Pharmaceuticals • Astrazeneca • Protagonist Therapeutics • Abbvie • Endo International • Blueprint Medicines • Iterum Therapeutics • Entasis TherapeuticsRisks
- The commercial success of GIAPREZA and XERAVA will depend on our ability to obtain an uninterrupted supply of GIAPREZA and XERAVA from our contract manufacturers.
- Product liability or other lawsuits against us could cause us to incur substantial liabilities and reduce GIAPREZA and XERAVA sales.
- Our ability to continue commercializing GIAPREZA is dependent on our fulfillment of contractual obligations under the royalty financing agreement with HealthCare Royalty Partners.
- The commercial success of GIAPREZA and XERAVA in certain ex-U.S. territories is dependent on the fulfillment of contractual obligations under the Company’s out-license agreements.
- Our overall financial performance, including but not limited to, net product sales and net cash used for or provided by operating activities, may not meet our expectations.
- Our capital requirements and our potential need for, and ability to obtain, additional financing are uncertain.
- Future utilization of net operating loss carryforwards or research and development credit carryforwards may be impaired due to changes in ownership.
- Our ability to hire and retain key employees is uncertain.
- Our employees may engage in misconduct, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
- Failure to obtain regulatory approval in international jurisdictions would prevent our products, our product candidates or any other products the Company or its current or future out-licensees may develop from being marketed abroad.
- We may not be successful in our efforts to out-license our product candidates.
- GIAPREZA’s and XERAVA’s market exclusivity periods will depend on the validity and enforceability of issued and pending patents covering GIAPREZA and XERAVA.
- If we fail to comply with our obligations under our in-license agreements, we may lose rights to critical patents that are important to the commercialization and net sales potential of GIAPREZA and XERAVA.
- If our products or our product candidates infringe the rights of others, we could be subject to expensive litigation, become liable for substantial damages, be required to obtain licenses from others or be prohibited from selling our products or product candidates altogether.
- Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.
- We are subject to various federal, state and foreign laws and regulations governing the health care industry that could result in substantial penalties for noncompliance.
- Drugs approved by the FDA, EC and/or other regulatory agencies are subject to ongoing regulation.
- Business interruptions resulting from geopolitical actions, natural disasters, public health crises or other catastrophic events could have an adverse impact on our business.
- The price per share of our common stock may fluctuate significantly, and you may lose all or part of your investment.
- We have never paid a dividend on shares of our common stock, and you should rely on price appreciation of shares of our common stock for return on your investment.
- Conversion of our convertible preferred stock would result in substantial dilution for our existing common stockholders.
- Our directors, executive officers and principal stockholders have substantial control over the Company, which could limit your ability to influence the outcome of key transactions, including a change of control.
- Our business and operations may be materially adversely affected in the event of computer system failures or security breaches.
Management Discussion
- Net product sales consist of revenue recognized from sales of GIAPREZA and XERAVA to hospitals and other healthcare organizations in the U.S., generally through a network of specialty distributors. These specialty distributors are considered our customers for accounting purposes.
- For the three months ended March 31, 2022, La Jolla’s net product sales were $10.4 million compared to $8.6 million for the same period in 2021, an increase of 21%. GIAPREZA U.S. net product sales were $7.7 million for the three months ended March 31, 2022 compared to $6.8 million for the same period in 2021, an increase of 13%. XERAVA U.S. net product sales were $2.7 million for the three months ended March 31, 2022 compared to $1.8 million for the same period in 2021, an increase of 50%. The increase in GIAPREZA and XERAVA U.S. net product sales is primarily due to an increase in the number of vials sold to our customers.
- License and other revenue consists of revenue from out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development, regulatory or commercial milestone payments; and/or (iii) sales-based royalties. License and other revenue also consists of revenue from commercial supply agreements with our out-licensees to supply a minimum quantity of our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Abbreviated, AcelRx, adverse, alternative, ANDA, announced, asserted, Authority, Book, certification, chemical, complaint, Court, discontinued, discretion, District, enforce, equal, Equivalence, extend, forward, free, Gland, growing, infringed, infringement, invalid, Jersey, Letter, listed, Lowell, manner, modestly, notified, offer, option, Orange, paragraph, pediatric, preclinical, privately, purpose, repurchase, repurchased, Science, study, succeeding, support, Therapeutic, unenforceable, unrealized, version, vigorously
Removed:
accelerated, accounted, acquirer, amortized, annually, annum, assumed, audit, aware, California, cancellable, care, case, charge, chief, Code, combination, commercialized, decreased, deductible, determination, Diego, diligence, discounted, effort, eventual, exceed, exclude, exist, expensed, extent, final, forfeited, goodwill, guaranteed, headcount, Identifiable, impairment, incurred, indefinite, initially, June, life, litigation, Merger, model, monthly, occurrence, operational, ordinary, participant, patient, payroll, penalty, permitted, perspective, platform, presented, produced, profit, project, qualitative, quantitative, Raw, realignment, recover, recoverable, reduced, repay, replacement, residual, restructuring, revision, San, September, stronger, terminal, test, threatened, trade, treat, TTP, undiscounted, unforgiven, unsecured, utility, viewpoint, wholesale, written
Financial reports
Current reports
8-K
Other Events
16 Feb 22
8-K
La Jolla Pharmaceutical Company Announces Share Repurchase Plan
18 Nov 21
8-K
Submission of Matters to a Vote of Security Holders
27 Jul 21
8-K
Entry into a Material Definitive Agreement
12 Jan 21
8-K
Termination of a Material Definitive Agreement
18 Dec 20
8-K
Changes in Registrant's Certifying Accountant
5 Nov 20
8-K
Departure of Directors or Certain Officers
30 Oct 20
8-K/A
Financial Statements and Exhibits
13 Oct 20
8-K
Departure of Directors or Certain Officers
2 Oct 20
8-K
Departure of Directors or Certain Officers
17 Sep 20
Registration and prospectus
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Nov 21
8-K12B
Notification of registration of securities
2 Nov 21
SC TO-T/A
Third party tender offer statement (amended)
28 Jul 20
SC TO-T
Third party tender offer statement
29 Jun 20
SC TO-C
Information about tender offer
24 Jun 20
SC TO-C
Information about tender offer
22 Jun 20
Other
CORRESP
Correspondence with SEC
13 May 20
UPLOAD
Letter from SEC
12 May 20
UPLOAD
Letter from SEC
15 Oct 19
CORRESP
Correspondence with SEC
8 Oct 19
UPLOAD
Letter from SEC
25 Sep 19
CORRESP
Correspondence with SEC
18 Sep 19
UPLOAD
Letter from SEC
25 Aug 19
EFFECT
Notice of effectiveness
26 Oct 18
CORRESP
Correspondence with SEC
22 Oct 18
UPLOAD
Letter from SEC
22 Oct 18
Ownership
4
LA JOLLA PHARMACEUTICAL / Michael S Hearne ownership change
17 Jun 22
4
LA JOLLA PHARMACEUTICAL / Michael S Hearne ownership change
2 Jun 22
4
LA JOLLA PHARMACEUTICAL / Michael S Hearne ownership change
17 May 22
4
LA JOLLA PHARMACEUTICAL / Michael S Hearne ownership change
3 May 22
4
LA JOLLA PHARMACEUTICAL / Larry G. Edwards ownership change
18 Apr 22
4
LA JOLLA PHARMACEUTICAL / Michael S Hearne ownership change
18 Apr 22
4
LA JOLLA PHARMACEUTICAL / Larry G. Edwards ownership change
4 Apr 22
4
LA JOLLA PHARMACEUTICAL / Michael S Hearne ownership change
4 Apr 22
4
LA JOLLA PHARMACEUTICAL / Larry G. Edwards ownership change
17 Mar 22
4
LA JOLLA PHARMACEUTICAL / Michael S Hearne ownership change
17 Mar 22
Patents
Utility
Compositions and Methods for Treating Renal Failure
23 Jun 22
The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.
Utility
Angiotensin Compositions and Methods Related Thereto
26 May 22
Provided herein are dosage forms and kits comprising angiotensin II that are suitable for the treatment of low blood pressure.
Utility
Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
11 Jan 22
The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
Utility
Methods for Administering Angiotensin II
24 Jun 21
The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
Utility
Methods of Administering Hepcidin
6 May 21
The present disclosure relates to the use of hepcidin in therapeutic methods for the treatment of various conditions in which decreasing serum iron concentration may be beneficial.
Reddit threads
Daily Discussion Thread - May 17th, 2022
17 May 22
Daily Discussion Thread - May 13th, 2022
13 May 22
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - May 6th, 2022
6 May 22
Daily Discussion Thread - May 5th, 2022
5 May 22
Daily Discussion Thread - November 5th, 2021
5 Nov 21
Daily Discussion Thread - August 5th, 2021
5 Aug 21
Daily Discussion Thread - August 4th, 2021
4 Aug 21